GLP-1 and Weight-Loss Drug Advertising Rules in 2026: Meta, Google and TikTok Compliance for Telehealth Brands

How Meta, Google and TikTok classify GLP-1 and weight-loss drug ads

GLP-1 and weight-loss drug ads are not reviewed as ordinary performance creative. Each platform files them under a restricted healthcare category with its own certification gate, claim rules and enforcement path — and the classification differs by platform.

Google: a certification-gated healthcare category

Google's Healthcare and medicines policy restricts promotion of services related to the online prescribing, dispensing and sale of prescription drugs, and it explicitly names online pharmacies and telemedicine providers as in-scope businesses. Three sub-policies drive most GLP-1 disapprovals:

• Prescription drug services — advertisers must apply and be approved before serving ads.
• Restricted drug terms — prescription drug terms are restricted in ads, landing pages and keywords, with location-dependent exceptions.
• Unapproved substances — Google maintains a non-exhaustive list of banned pharmaceuticals and supplements, including products that imply they're as effective as prescription drugs and hCG products marketed for weight loss.

Where does enforcement attach? Google's unauthorized-pharmacy enforcement is ad-account-level: Google Ads accounts are suspended upon detection, without prior warning — the penalty is not limited to the individual ad. Certified campaigns that target allowed locations with a properly certified domain typically serve as "Eligible (limited)."

Meta: a claims-and-targeting policy plus business registration

Meta's Health and Wellness policy treats weight-loss and weight-gain products and services as restricted: ads must target people 18 or older, and prohibited content includes statements of inferiority about physical appearance and close-ups that pinch fat. Separately, healthcare businesses on Meta must register as health-related and meet platform-specific creative requirements — a business-level registration, not a personal-profile setting. The reviewed Meta policy text governs ad content and targeting; it does not spell out separate enforcement at the ad-account, Page or Business Portfolio level, so plan on content-level disapprovals plus business-level registration. Meta's policy pages reviewed here also do not document a review timeline or a defined appeal outcome — treat approval timelines as variable, not predictable.

TikTok: a flat prohibition on the commerce side

TikTok Shop's requirements for responsible health-related content (dated September 2, 2026 in the source) state that weight-loss/muscle-gain products and GLP/GLP-1 promotions are not allowed, and non-compliance can lead to content removal. This evidence covers TikTok Shop's seller requirements; TikTok's in-feed ads policies are separate documents not included in this evidence set — verify them directly rather than assuming parity.

What the three have in common

• Automated systems flag health-related ads on keywords and content signals, so even certified, compliant creative can be flagged mid-flight and require a dispute.
• Your classification drives your rules: on Google, requirements differ for telemedicine providers, online pharmacies, pharmaceutical manufacturers and addiction services providers.
• None of these restrictions are lifted by running through an agency ad account — certification and policy requirements attach to the advertiser, the domain and the offer, not to the account wrapper.

Prescription drug and online pharmacy rules: certification and eligible countries

The certification stack, in order

For U.S. telehealth brands the Google path is two-step: external accreditation first, then Google's own certification.

1. External accreditation. Telemedicine providers must be accredited by LegitScript's Healthcare Merchant Certification Program, which certifies websites providing virtual healthcare and facilitating prescribing. Online pharmacies can use LegitScript's internet pharmacy certification (sites accepting refills, transfers or new prescriptions, or filling via mail order or remote ordering) or NABP options — Digital Pharmacy Accreditation or a .pharmacy domain under the Healthcare Merchant Accreditation Program.
2. Google certification. After accreditation, advertisers must also apply to and be certified by Google before serving prescription drug services ads.

For Google Merchant Center (Shopping and free listings), prescription drug listings are currently allowed only in the United States and Canada, and only for online pharmacies accredited by LegitScript, NABP's VIPPS program or the Pharmacy Verified Websites Program — then certified with Google.

Eligible countries expanded in 2026 — re-check, don't assume

• New Zealand (April 2026): LegitScript-certified telemedicine providers may promote prescription drug services.
• India (April 2026): certified online pharmacies may promote prescription drug services — but advertisers targeting India still may not promote prescription drugs in ads or landing pages.
• Spain (August 2026): LegitScript-certified telemedicine providers may promote prescription drug services.

Even in allowed markets, restricted drug terms rules commonly bar drug names from ad text, landing pages and keywords — Australia, for example, bans prescription drug terms in the ad or its destination, and the UK bars promoting prescription drugs in ads and landing pages. Check the location-specific restrictions for every market before launch.

Billing and offer structure: the March 2026 recurring billing change

Starting March 31, 2026, Google Merchant Center allows certified U.S. online pharmacies to run prescription drug subscriptions (recurring billing), prescription drug bundles — including drugs bundled with weight-loss programming or coaching, as long as the prescription drug is the primary product — and prescription drug consultation services, including recurring eligibility evaluations. The feed and billing requirements: submit the [subscription_cost] attribute with the total, non-discounted periodic payment, link subscription terms and conditions in the return policy field, disclose all fees, and state explicitly what the offer includes ("prescription drug only" vs. a bundled treatment plan).

Enforcement: two different regimes

• Unauthorized pharmacies (egregious): offering prescription drugs without a prescription, or targeting locations where you aren't licensed, can suspend Google Ads accounts upon detection, without prior warning. Reinstatement happens only in compelling circumstances.
• The 2026 country-specific telemedicine rules: violations trigger a warning at least 7 days before any suspension — a materially different posture.

Portability, ownership and account structure

Certifications attach to the advertiser and domain, not to an individual media buyer. If you operate multiple managed accounts under one Manager Account (MCC), Manager Account Certification can apply an existing healthcare certification to those additional managed accounts — so plan ownership, admin and partner access, MCC structure, and how certifications move during agency onboarding or offboarding before you scale spend. LegitScript certification is recognized by Google, Meta and Microsoft, but every platform layers its own policies on top; certification is the entry ticket, not an exemption.

Compounded GLP-1 medications: what the FDA has said and why it affects ad review

What the FDA has actually said

• Compounded drugs are not FDA-approved; FDA does not review them for safety, effectiveness or quality before marketing. They are not generic drugs, which are FDA-approved.
• On March 3, 2026, FDA announced 30 warning letters to telehealth companies making false or misleading claims about compounded GLP-1 products on their websites — the second group of letters since the agency's September crackdown on misleading direct-to-consumer pharmaceutical ads.
• FDA has separately warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide.

The claim patterns FDA flagged

FDA's guidance to telehealth companies lists the claims to strip out of any compounded GLP-1 funnel:

• Branding that implies the telehealth company is the compounder (the March 2026 letters cite branding that obscured product sourcing).
• Describing a compounded drug as a generic version of, or the same as, an FDA-approved drug.
• Claiming a compounded drug is FDA-approved or FDA-evaluated.
• Describing it as clinically proven to produce the same result as the FDA-approved drug.
• Claiming it is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility — FDA does not approve or license any facility.

Where compounding legality stands

Section 503A requires patient-specific prescriptions and bars compounding drugs that are essentially copies of commercially available drugs "regularly or in inordinate amounts"; FDA's current posture is not to act on essentially-copy products when a compounder fills four or fewer prescriptions of that product per calendar month. Section 503B outsourcing facilities may only compound from bulk substances on the 503B bulks list or drugs on FDA's shortage list — and as of FDA's April 2026 update, tirzepatide and semaglutide appear on neither. FDA determined the semaglutide injection shortage was resolved in February 2025 and the tirzepatide shortage was resolved in December 2024, closing the enforcement-discretion windows that had allowed compounding during the shortages.

Why this lands on ad review

Platforms and their reviewers treat compounded GLP-1 promotion as elevated-risk. LegitScript monitored more than 500,000 paid search ads referencing GLP-1s in a two-month period and detected a 12x increase in violative or problematic ads since 2022; 83% of the violative ads it reported ran in jurisdictions where prescription-medicine ads are not allowed, and 15% offered GLP-1s without a prescription. Compounding pharmacies claiming their GLP-1s are FDA-approved are a violation category in their own right. FDA's standing guidance: weight-loss drugs should be obtained only with a prescription from a licensed provider, and only from state-licensed pharmacies or FDA-registered outsourcing facilities.

Practitioner guidance is blunt: compounded GLP-1s are not the same as branded versions and may not be marketed as replacements for them — equivalency language falls outside FDA guidance. If your program includes compounded semaglutide or tirzepatide, treat every claim as regulatory surface area and involve counsel. This guide is not legal or medical advice.

Weight-loss claims, before-and-after images and body-image restrictions

Meta's documented creative limits

• Targeting: 18+ only for dietary, health, weight-loss or weight-gain products and services.
• Prohibited: statements of inferiority about physical appearance — negative terms, descriptions or questions that attack a person's appearance, specific body parts or hygiene — and depictions such as a close-up of a body area being pinched.
• Allowed for 18+: ads can illustrate people using the product or service and its impact, if they clearly indicate the time taken to achieve noticeable results.

Claims: the substantiation bar

A specific outcome claim must be substantiated by clinical trial data — and per LegitScript's webinar panel, most weight-loss percentages and transformation-focused messaging do not clear that bar. The FTC position relayed by the same panel: a "results not typical" disclaimer is no longer sufficient cover for atypical outcomes, and patient stories must be representative of how the average consumer would actually experience the product.

Before-and-after imagery

Before-and-after visuals are among the most common substantive rejection reasons for healthcare ads, alongside unsubstantiated claims, missing disclosures and mentions of restricted drug names. The working guidance: avoid them in the ads themselves. If they are used at all, they belong on landing pages with full disclosures — that results are representative of typical outcomes, that the person depicted is a real patient, and that any monetary relationship between the brand and the patient is disclosed.

Google's claim restrictions

• Products that imply they are as effective as prescription drugs or controlled substances are banned under the unapproved substances policy — the rule most relevant to any supplement positioned as comparable to a GLP-1.
• Products containing hCG promoted for weight loss or weight control are banned outright.
• For Spain, Google Merchant Center disallows weight-loss-related listings that claim medicinal properties, promise specific results, or use endorsements by individuals, celebrities or organizations.
• FDA rules sit on top of platform policy for prescription drugs: advertisements that are false, lacking in fair balance or otherwise misleading are prohibited under 21 CFR 202.1(e)(6), 21 USC 321(n) and 21 USC 352.

Lower-risk messaging directions

Consumer awareness of GLP-1s is already high, so effective campaigns do not need outcome claims: access, cost, the clinical experience and the convenience of telehealth-based care can carry the message. Treat that as a lower-risk theme set, not a guarantee of approval — automated filters flag compliant health ads too, and policies change.

TikTok Shop weight-management product rules

TikTok Shop is the bluntest of the three surfaces. Its requirements for responsible health-related content (dated September 2, 2026 in the source) state that weight-loss/muscle-gain products and GLP/GLP-1 promotions are not allowed, and non-compliance can lead to content removal.

What this means for telehealth and weight-management brands:

• No GLP-1 offers through TikTok Shop listings. Unlike Google and Meta, which allow certified advertisers under defined conditions, the TikTok Shop rule documented here is a flat prohibition for this category — no certification pathway is described in the reviewed policy text.
• Commerce rules and ads rules are different documents. The evidence here covers TikTok Shop's seller requirements. TikTok's advertising policies are not included in this evidence set — verify current ad rules directly with TikTok before planning campaigns, and do not assume Shop and ads policies match.
• Read the full policy. The reviewed text is a condensed summary with truncated enforcement details (it also references over-the-counter product categories), so treat it as directional and confirm specifics in TikTok Shop's current seller documentation before listing anything adjacent to weight management.

For brands spending $100K+/month, the practical read: use TikTok for organic and educational content, route acquisition to channels with documented certified pathways, and keep any educational weight-management content clearly separate from product offers. No platform outcome is guaranteed — and none of these rules are lifted by account infrastructure alone.

A pre-launch checklist for GLP-1 creatives and landing pages

Run this before any GLP-1 creative or landing page goes live. At $100K+/month in spend, one policy strike costs more than the review time.

1. Confirm your classification. Decide where you sit in each platform's taxonomy — telemedicine provider, online pharmacy or pharmaceutical manufacturer on Google; health-related business registration on Meta. Most telehealth providers classify as telemedicine rather than pharmacy unless they own and operate their own pharmacy, and the classification determines which treatments you may promote and what documentation the platform requires.

2. Stack certifications in order. LegitScript (or NABP accreditation for pharmacies) → Google healthcare certification → load the certification into the platform before launch, with supporting documentation on hand. If you run multiple managed accounts under one MCC, apply for Manager Account Certification so the certification covers them. Document ownership, admin and partner access, billing setup, and how certifications and domains move if you change agencies or infrastructure — offboarding should preserve certification status and domain continuity, not just hand over ad accounts.

3. Re-check eligible countries at launch time. The 2026 updates moved the map (New Zealand and India in April, Spain in August). Verify restricted drug terms rules per market — drug names are barred from ads, landing pages and keywords in many countries even where the service itself may be promoted.

4. Audit the landing page. Disclose that treatment requires a prescription, that licensed providers are involved and that a medical consultation is part of the process. No FDA-approval claims for compounded formulations. No guaranteed results. For Merchant Center subscription offers: [subscription_cost] attribute, subscription terms linked in the return policy field, all fees disclosed, and an explicit statement of what the offer includes.

5. Screen creative against the known rejection reasons. Unsubstantiated claims; missing disclosures; mentions of restricted drug names; before-and-after imagery. On Meta add: 18+ targeting, no statements of inferiority about physical appearance, no pinching-fat close-ups, and if the ad shows the product's impact, indicate the time taken to achieve noticeable results.

6. Kill equivalency language. No "generic," "same as," "FDA-approved," "clinically proven to match" or "FDA-licensed facility" claims for compounded GLP-1s — these are the exact patterns FDA's warning letters cite. Compounded GLP-1s are not the same as branded versions and may not be marketed as replacements for them.

7. Substantiate or soften outcome claims. Specific outcome claims need clinical trial data; weight-loss percentages and transformation messaging generally do not clear the bar. Test access, cost, clinical experience and convenience angles instead.

8. Separate prescription and OTC campaigns. A campaign is always subject to the requirements of its most regulated product — use distinct landing pages, ad sets and, where possible, distinct accounts for Rx vs. OTC offers.

9. Treat disapprovals as routine. Automated filters flag health ads even when compliant. Keep documentation organized, backup creative approved and queued, and a clear dispute process — once a human reviews a flagged ad, many flags turn out to be errors. Assign one owner to track platform policy and FDA/FTC changes across all active campaigns. Note the asymmetry: Google's unauthorized-pharmacy enforcement suspends accounts without prior warning, while the newer country-specific telemedicine rules carry at least 7-day warnings — and Meta does not publish a documented review timeline in the policy pages reviewed here, so plan buffer time.

10. No guarantees. FDA guidance, Google's country-specifics and TikTok Shop rules all moved within 2026 alone — re-verify at launch and re-audit monthly.

Talk to an AdsInfra specialist about ad account infrastructure for certified telehealth teams spending $100K+/month.